RESEARCH MONOGRAPH · KDC-MN-063

Bromantane

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

65/100

Slept-on Russian adaptogen with a real dopamine-tyrosine-hydroxylase mechanism that western literature mostly ignores

Bromantane is one of those compounds where the western literature gap is almost embarrassing. The Russians (Vakhitova, Mikhaylova, the Zakharova group at the Institute of Pharmacology) have been working on this molecule since the 80s, originally as an anti-asthenic for Soviet military and cosmonaut use, and they actually mapped a mechanism that no western nootropic supplier ever bothered to investigate properly.

Here's the thing. Bromantane isn't a stimulant in the classical sense. It upregulates tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the ventral tegmental area, which means it increases the rate-limiting enzyme of dopamine biosynthesis rather than just dumping monoamines out of vesicles like amphetamine does. So you get a slow build of catecholamine tone instead of a release-and-crash profile. The GABAergic component is the part most write-ups miss; it's the combination of mild GABA potentiation plus dopaminergic synthesis upregulation that gives the anti-asthenic profile.

What we like is the genuinely unusual pharmacology. Adamantane scaffold, lipophilic enough to cross BBB readily, and the Russian clinical trial literature on asthenia and SSRI-resistant depression is actually not bad if you can read Russian. Mikhaylova 2007 and subsequent work showed dose-dependent effects on locomotor activity and dopamine turnover that have replicated across multiple labs.

What we dont like: the western evidence base is genuinely thin. There are essentially no GMP human trials outside Russia, the WADA banned it after Krushelnitckii tested positive at 2018 Olympics (which tells you it does something pharmacologically real), and sourcing varies wildly. The 2-3 reputable suppliers do clean HPLC, the rest is sketchy.

Mechanism score should be higher than people assume because the Russian biochem work is solid. Reliability is the open question. Researchers we talk to report either clear stimulant-without-anxiety effects or basically nothing, with not much middle ground, which suggests genotype or baseline dopamine tone matters more than dose.

Worth investigating? yeah, especially if you're interested in catecholamine biosynthesis pathways rather than monoamine release. Just don't expect modafinil or amphetamine; it's its own thing.

Evidence: 45
Mechanism: 72
Reliability: 58
Safety: 78
Sourcing: 65
Value: 70
Signal: 68
Staying power: 60

Plain-language summary Intrigue 62 / 100

Bromantane is a Russian-developed adamantane-derived adaptogen used to enhance physical and mental performance. It modulates dopamine and serotonin systems and is approved in Russia for asthenia. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Adamantane-derived adaptogen

A Soviet-developed adamantane derivative (Ladasten) approved in Russia for asthenia with mixed psychostimulant and anxiolytic effects.

Abstract

Bromantane (Ladasten; ADK-709; N-(2-adamantyl)-N-(p-bromophenyl)amine; CAS 87913-26-6; molecular formula C16H20BrN; molecular weight 306.24) is an adamantane derivative developed in the Soviet Union in the 1980s, originally for military applications (combat fatigue, cold tolerance). The compound is approved in Russia as Ladasten for asthenia and neurasthenia. Pharmacology is distinctive: bromantane combines mild dopaminergic activation (through enhanced dopamine synthesis rather than transporter inhibition or release) with anxiolytic effects through a non-GABAergic mechanism. The combination produces a clinical profile described as "actoprotective" . improving physical and mental performance under stress without the rebound fatigue typical of stimulants or the sedation typical of anxiolytics. Bromantane is on the WADA prohibited list (banned in 1996). Pharmacokinetics: plasma half-life 9 to 12 hours; oral bioavailability good. Reported research dose ranges in the literature are described in the source monograph. Russian clinical literature is substantial; English-language randomized trials are limited.

Mechanism of action

Mild dopaminergic activation through enhanced synthesis (not DAT inhibition). Anxiolytic effects through non-GABAergic mechanism. Actoprotective profile.

Reported research dose ranges

50 to 100 mg (reported research dose range).

References

Vakhitova IV, et al. Bromantane mechanism of action and clinical pharmacology. Russian J Pharmacol 2000s.
Morozov IS, et al. Bromantane: an actoprotective drug. Russian Academy of Medical Sciences publications.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, reported research dose ranges, sourcing and quality verification, reconstitution and handling, stack interaction considerations, and a curated reference list. Available as a research-use-only PDF download.

KDC-MN-063

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Bromantane

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs